Reinforcing Gaps? A Rapid Review of Innovation in Borderline Personality Disorder (BPD) Treatment

Cailhol, Lionel, St-Amour, Samuel ORCID: https://orcid.org/0000-0002-6282-7885, Désilets, Marie, Larivière, Nadine, Mills, Jillian et Klein, Rémy (2025). Reinforcing Gaps? A Rapid Review of Innovation in Borderline Personality Disorder (BPD) Treatment. Brain Sciences, 15 (8). (827).

PDF Licence d'utilisation : CC BY 4.0. Télécharger (630kB) | Prévisualisation

Résumé

Background/Objectives: Borderline Personality Disorder (BPD) involves emotional dysregulation, interpersonal instability and impulsivity. Although treatments have advanced, evaluating the latest innovations remains essential. This rapid review aimed to (1) identify and classify recent therapeutic innovations for BPD, (2) assess their effects on clinical and functional outcomes, and (3) highlight research gaps to inform future priorities.

Methods: Employing a rapid review design, we searched PubMed/MEDLINE, PsycINFO, and Embase for publications from 1 January 2019 to 28 March 2025. Eligible studies addressed adult or adolescent BPD populations and novel interventions—psychotherapies, pharmacological agents, digital tools, and neuromodulation. Two independent reviewers conducted screening, full-text review, and data extraction using a standardised form.

Results: Sixty-nine studies—predominantly from Europe and North America—were included. Psychotherapeutic programmes dominated, ranging from entirely novel models to adaptations of established treatments (for example, extended or modified Dialectical Behavior Therapy). Pharmacological research offered fresh insights, particularly into ketamine, while holistic approaches such as adventure therapy and digital interventions also emerged. Most investigations centred on symptom reduction; far fewer examined psychosocial functioning, mortality, or social inclusion.

Conclusions: Recent innovations show promise in BPD treatment but underserve the needs of mortality and societal-level outcomes. Future research should adopt inclusive, equity-focused agendas that align with patient-centred and recovery-oriented goals, supported by a coordinated, integrated research strategy.

Type de document :	Article
Validation par les pairs :	Oui
Mots-clés :	Trouble de la personnalité ; Psychothérapie ; Neuromodulation ; Médicaments psychotropes ; Fonctionnement psychosocial ; Mortalité ; Suicide ; Innovation ; Comorbidité ; Stimulation cérébrale ; Psychotrope / Personality disorder ; Psychotherapy ; Neuromodulation ; Psychotropic drugs ; Psychosocial functioning ; Mortality ; Suicide ; Innovation ; Comorbidity ; Brain stimulation ; Psychotropic .
Départements et unités départementales :	Département des sciences de la santé
Date de dépôt :	30 sept. 2026 18:08
Dernière modification :	06 oct. 2026 14:47
URI :	https://semaphore.uqar.ca/id/eprint/3661